The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

SMA Europe is a non-profit organisation.

SMA Europe

The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

SMA Europe is a non-profit organisation.

Latest News

09/08/2016

Development of LMI070: Novartis provides community update

Novartis has a product in clinical trial for SMA and wish to share the following update on the development of LMI070. In May, we shared with you news of the difficult decision to pause enrollment for our study of LMI070 for the treatment of Type 1 Spinal Muscular Atrophy (SMA). This decision was made because […]

03/08/2016

Nusinersen questions and answers on the latest developments

In response to a request made by SMA Europe, Biogen has supplied us with a Nusinersen questions and answers (Q&Q) sheet to further explain the significance of the announcement the companies made on 1st August, regarding the development of Nusinersen. Please find the questions and answers below: On August 1, 2016 Biogen and Ionis Pharmaceuticals […]

01/08/2016

Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset SMA

Biogen and Isis Pharmaceuticals are delighted to announce that Nusinersen has met the primary endpoint in an interim analysis of the phase 3 ENDEAR Study in infants with Infantile-Onset SMA. Please read below the companies’ statement: Dear Members of the SMA Community, Today marks an important day in our collective pursuit of a meaningful treatment […]

Latest Projects